These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 35582722)

  • 21. Molecular basis of the Keap1-Nrf2 system.
    Suzuki T; Yamamoto M
    Free Radic Biol Med; 2015 Nov; 88(Pt B):93-100. PubMed ID: 26117331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FoxO proteins: regulation and molecular targets in liver cancer.
    Carbajo-Pescador S; Mauriz JL; García-Palomo A; González-Gallego J
    Curr Med Chem; 2014 Apr; 21(10):1231-46. PubMed ID: 24372208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer.
    Liu Z; Zhu G; Getzenberg RH; Veltri RW
    J Cell Biochem; 2015 Jul; 116(7):1341-9. PubMed ID: 25640606
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Yeast
    Siswanto FM; Tamura A; Sakuma R; Imaoka S
    Mol Pharmacol; 2022 Apr; 101(4):257-273. PubMed ID: 35193967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chrysin enhances sensitivity of BEL-7402/ADM cells to doxorubicin by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathway.
    Gao AM; Ke ZP; Shi F; Sun GC; Chen H
    Chem Biol Interact; 2013 Oct; 206(1):100-8. PubMed ID: 23994249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nrf2 is controlled by two distinct β-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity.
    Chowdhry S; Zhang Y; McMahon M; Sutherland C; Cuadrado A; Hayes JD
    Oncogene; 2013 Aug; 32(32):3765-81. PubMed ID: 22964642
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DJ-1 is involved in the multidrug resistance of SGC7901 gastric cancer cells through PTEN/PI3K/Akt/Nrf2 pathway.
    Qiu L; Ma Z; Li X; Deng Y; Duan G; Zhao LE; Xu X; Xiao L; Liu H; Zhu Z; Chen H
    Acta Biochim Biophys Sin (Shanghai); 2020 Dec; 52(11):1202-1214. PubMed ID: 33079995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genome-wide global identification of NRF2 binding sites in A549 non-small cell lung cancer cells by ChIP-Seq reveals NRF2 regulation of genes involved in focal adhesion pathways.
    Namani A; Liu K; Wang S; Zhou X; Liao Y; Wang H; Wang XJ; Tang X
    Aging (Albany NY); 2019 Dec; 11(24):12600-12623. PubMed ID: 31884422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression.
    Nakanishi T; Ross DD
    Chin J Cancer; 2012 Feb; 31(2):73-99. PubMed ID: 22098950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual regulation of transcription factor Nrf2 by Keap1 and by the combined actions of β-TrCP and GSK-3.
    Hayes JD; Chowdhry S; Dinkova-Kostova AT; Sutherland C
    Biochem Soc Trans; 2015 Aug; 43(4):611-20. PubMed ID: 26551701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The discovery and characterization of K-563, a novel inhibitor of the Keap1/Nrf2 pathway produced by Streptomyces sp.
    Hori R; Yamaguchi K; Sato H; Watanabe M; Tsutsumi K; Iwamoto S; Abe M; Onodera H; Nakamura S; Nakai R
    Cancer Med; 2019 Mar; 8(3):1157-1168. PubMed ID: 30735010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Keap1-Nrf2 pathway: A promising target towards lung cancer prevention and therapeutics.
    Tong YH; Zhang B; Fan Y; Lin NM
    Chronic Dis Transl Med; 2015 Sep; 1(3):175-186. PubMed ID: 29063005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy.
    Tamburrino A; Piro G; Carbone C; Tortora G; Melisi D
    Front Pharmacol; 2013; 4():56. PubMed ID: 23641216
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulatory role of the transforming growth factor-β signaling pathway in the drug resistance of gastrointestinal cancers.
    Lv X; Xu G
    World J Gastrointest Oncol; 2021 Nov; 13(11):1648-1667. PubMed ID: 34853641
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TGF-β-induced phosphorylation of Akt and Foxo transcription factors negatively regulates induced regulatory T cell differentiation.
    Kurebayashi Y; Baba Y; Minowa A; Nadya NA; Azuma M; Yoshimura A; Koyasu S; Nagai S
    Biochem Biophys Res Commun; 2016 Nov; 480(1):114-119. PubMed ID: 27697523
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Emerging Role of Non-coding RNAs in Drug Resistance of Ovarian Cancer.
    Lan H; Yuan J; Zeng D; Liu C; Guo X; Yong J; Zeng X; Xiao S
    Front Genet; 2021; 12():693259. PubMed ID: 34512721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds.
    Carrella D; Manni I; Tumaini B; Dattilo R; Papaccio F; Mutarelli M; Sirci F; Amoreo CA; Mottolese M; Iezzi M; Ciolli L; Aria V; Bosotti R; Isacchi A; Loreni F; Bardelli A; Avvedimento VE; di Bernardo D; Cardone L
    Oncotarget; 2016 Sep; 7(37):58743-58758. PubMed ID: 27542212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Hippo pathway in chemotherapeutic drug resistance.
    Zhao Y; Yang X
    Int J Cancer; 2015 Dec; 137(12):2767-73. PubMed ID: 25348697
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates to promote epithelial cell transformation and resistance to targeted therapies.
    Cipriano R; Miskimen KL; Bryson BL; Foy CR; Bartel CA; Jackson MW
    Oncotarget; 2013 May; 4(5):729-38. PubMed ID: 23676467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of the NRF2/KEAP1 Axis: A Promising Therapeutic Strategy to Alter Redox Balance of Cancer Cells.
    Panieri E; Saso L
    Antioxid Redox Signal; 2021 Jun; 34(18):1428-1483. PubMed ID: 33403898
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.